Neurocrine Biosciences' license with Heptares effective; $100M upfront due

NEUROCRINE BIOSCIENCES INC

Collaboration and License Agreement with Heptares Therapeutics becomes effective Dec 22, 2021 after HSR clearance.
Neurocrine to pay Heptares $100M upfront within ten days of effective date.
Agreement originally entered Nov 22, 2021; HSR waiting period expired Dec 22, 2021.

item 8.01

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-21-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.